Structure Therapeutics Inc. (GPCR) has a MoatMap StockRank of 39/100 based on Quality (44/100), Value (43/100), and Momentum (39/100) factor scores. The current signal is HOLD. Structure Therapeutics is a biotech company in drug discovery. The biotech sector is inherently high-risk and speculative, often driven by binary clinical trial outcomes rather than broad macro themes. It does not align with any specific, unpriced macro tailwinds identified, and the quality score (Q:44) is average.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oral small molecule therapeutics for chronic diseases, leveraging its proprietary G protein-coupled receptor (GPCR) targeting platform. The company's competitive moat stems from its specialized drug discovery capabilities focused on GPCRs, which are historically challenging yet highly validated drug targets, offering the potential for best-in-class oral therapies in significant disease areas. Structure Therapeutics represents a high-potential biotech firm aiming to address unmet medical needs through innovative pharmacological approaches.
| Price | $40.17 |
| Market Cap | $2.9B |
| P/E (Forward) | -20.28 |
| Price/Book | 1.85 |
| Return on Equity | -15.0% |
| Return on Invested Capital | -12.3% |
| Debt/Equity | 0.40 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
Structure Therapeutics Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).